Indications -- pain Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- pain

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: LJM	12/12/2006 12:14:06 PM
	of 101

Depomed Announces Strong Positive Phase II Trial Results For Once Daily Gabapentin GR(TM) To Treat Symptoms Of Diabetic Peripheral Neuropathy>DEPO Dec 12, 2006 07:54:00 (ET) DOW JONES NEWSWIRES Depomed Inc. (DEPO) said a Phase II trial of its Gabapentin GR drug for diabetic peripheral neuropathy showed statistically significant efficacy benefits. The Menlo Park, Calif., specialty pharmaceutical company said the trial involved 147 patients with diabetic peripheral neuropathy, a nerve disorder caused by diabetes. Patients were treated with 3,000-milligrams of Gabapentin GR, dosed once or twice daily, or a placebo. Reductions in average daily pain scores were statistically significant with the once-daily dose, and the twice-daily dose also showed pain improvement, Depomed said. Sleep interference also decreased with both doses. Depomed shares were up 48 cents, or 15%, at $3.60 in pre-market trading on Nasdaq. -Sara Leitch; 201-938-5400; AskNewswires@dowjones.com (END) Dow Jones Newswires

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next